secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-053933
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora Q1 net loss $53.7M; navacaprant Phase 3 MDD data on track for Q4 2024; NMRA-266 clinical hold with FDA
--------------------------------------------------------------------------------

- Net loss of $53.7M in Q1 2024 vs $35.6M in Q1 2023; R&D expense $45.8M, G&A $14.3M.
- Cash, cash equivalents and marketable securities of $423.0M; expected to fund operations into 2026.
- Topline Phase 3 data from navacaprant KOASTAL-1 in MDD expected Q4 2024; Phase 2 bipolar depression trial to start Q2 2024.
- NMRA-511 Phase 1 complete; Phase 1b in Alzheimer's agitation to start Q2 2024 with data in 2025.
- FDA placed clinical hold on NMRA-266 Phase 1 study; company working to resolve; additional M4 PAM IND expected 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000095017024053933/0000950170-24-053933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000095017024053933/nmra-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer